Discover Nyxoah’s Engaging Investor Events and Innovations
Nyxoah's Exciting Schedule of Investor Events
Nyxoah SA, a distinguished company in the medical technology sector, is thrilled to announce its participation in several pivotal investor events in September. These gatherings are a fantastic opportunity to engage with Nyxoah and learn more about their groundbreaking solutions for Obstructive Sleep Apnea (OSA), an area where they are making significant strides.
Major Conferences on the Horizon
Wells Fargo Healthcare Conference
The first event in the lineup is the Wells Fargo Healthcare Conference, scheduled for the 3rd of September. Investors and stakeholders will gather in Boston to discuss key developments and share insights into the company's future direction.
Cantor Global Healthcare Conference
Just a day later, on the 4th of September, Nyxoah will feature in the Cantor Global Healthcare Conference in New York. During this event, a special fireside chat is planned from 11:30 AM to 12:00 PM ET, allowing deeper interaction and discussion among healthcare aficionados. A webcast will also be available, ensuring that even those unable to attend in person can stay connected.
Morgan Stanley's Annual Global Healthcare Conference
Following these events, Nyxoah will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9th, where a presentation is scheduled between 5:35 PM to 6:10 PM ET. This conference aims to explore innovative healthcare solutions and strategies, and Nyxoah's involvement underscores their commitment to advancing healthcare technology.
The Baird Global Healthcare Conference
Concluding the September lineup is Baird's 2025 Global Healthcare Conference on the 10th of September in New York, which will also gather thought leaders in medical technology to foster discussions pertinent to future innovations.
Interactive Engagement Opportunities
Nyxoah's investor relations website will provide accessible live webcasts of the events, allowing a global audience to participate. After each event, recordings will be available, ensuring that crucial insights and discussions can be revisited. Moreover, 1x1 meetings with institutional investors will be organized, facilitating personalized conversations and connections.
About Nyxoah and Their Vision
Nyxoah is not just any medical technology company—they are at the forefront of developing innovative treatments for OSA. Their lead product, the Genio system, reflects their dedication to enhancing patient care by offering a leadless and battery-free hypoglossal neurostimulation therapy. This system aims to alleviate the symptoms of OSA, a condition that significantly impacts individuals’ health and quality of life.
The journey for Nyxoah has been remarkable. Since receiving European CE Mark approval for the Genio system in 2019, they have successfully completed two initial public offerings—first on Euronext Brussels in 2020, followed by Nasdaq in 2021. Their advancements continued with the positive results from the BETTER SLEEP study, which led to additional CE mark approvals. Recently, the company announced promising results from the DREAM IDE pivotal study along with U.S. FDA approval of a Premarket Approval application.
Continued Commitment to Innovation
Driven by the belief that patients with OSA deserve restful nights and energetic lives, Nyxoah is committed to pushing the boundaries of medical technology. They consistently strive for improvements that can lead to better health outcomes and enhance the overall patient experience.
Frequently Asked Questions
What events will Nyxoah participate in September?
Nyxoah will attend the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Annual Global Healthcare Conference, and Baird’s Global Healthcare Conference.
What is the Genio system?
The Genio system is a leadless, battery-free hypoglossal neurostimulation therapy designed to treat Obstructive Sleep Apnea.
Where can I access the live webcast for the events?
The live webcasts of the events will be available on Nyxoah’s Investor Relations website.
Has Nyxoah received regulatory approvals for their products?
Yes, Nyxoah's Genio system has received the European CE Mark and U.S. FDA approval as a prescription-only device.
Who can I contact for more information about Nyxoah?
For inquiries, you can contact John Landry, CFO of Nyxoah, via email at IR@nyxoah.com.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.